Ravi Agrawal releases pledge on 2,600 Ajanta Pharma shares

Promoter Ravi Agrawal released the pledge on 2,600 equity shares of ajanta pharma due to excess pledge, reducing the encumbered holding of the Ravi Agrawal Trust to 1,535,096 shares. The release, which occurred on July 9, 2026, was disclosed to the stock exchanges on July 13, 2026, under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The shares were previously pledged with HSBC Direct Invest Financial Services Pvt Ltd, with the depository participant being Barclays Securities (India) Private Limited. Following the release, the encumbered holding represents 1.23% of the total share capital of the company. The disclosure was submitted by Ravi Purushottam Agrawal in his capacity as trustee of the Ravi Agrawal Trust.

Shareholding Details

The filing provides a comprehensive overview of the promoter group's shareholding and encumbrance status as of the reporting date. The table below details the holdings of key promoters and the status of their encumbered shares.

Promoter Name	Total Holding	% of Share Capital	Encumbered Shares (Pre-event)	Encumbered Shares (Post-event)	% of Share Capital (Post-event)
Gabs Investments Pvt Ltd	12,588,393	10.08	2,770,000	2,770,000	2.22
Yogesh M Agrawal (Trustee)	18,078,147	14.47	-	-	-
Mannalal B Agrawal	0	0.00	-	-	-
Rajesh M Agrawal (Trustee)	18,078,148	14.47	-	-	-
Ravi P Agrawal (Trustee)	12,792,904	10.24	1,537,696	1,535,096	1.23
Ravi P. Agrawal	285,000	0.23	-	-	-
Aayush M Agrawal (Trustee)	14,112,924	11.30	13,532,924	13,532,924	10.83
Aayush M. Agrawal	30,000	0.02	0	30,000	0.02
Ganga Exports	3,348,261	2.68	-	-	-

The disclosure confirms that the release of pledge was a specific action taken by Ravi Agrawal to adjust the level of encumbrance against his holdings. The filing was addressed to BSE Limited and the National Stock Exchange of India for necessary record-keeping.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.04%	+5.31%	+13.04%	+28.79%	+27.99%	+138.34%

Promoters of Ajanta Pharma have revised their disclosures regarding the pledge of 66,32,651 equity shares to secure non-convertible debentures. The update, submitted to stock exchanges on July 7, 2026, specifies the entities in whose favor the encumbrance was created, naming 360 ONE Income Opportunities Fund series and 360 ONE Prime Ltd as the debenture holders, with CTL Trusteeship Limited acting as the security trustee. The original filing had only named the trustee.

The encumbrance was created on June 2, 2026, and June 30, 2026. The shares, representing 5.31% of the total share capital, were pledged by Aayush Agrawal Trust, Aayush Agrawal, and Gabs Investments Private Limited. The revision was made following a communication from BSE regarding a discrepancy in the earlier submission under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Details

The table below outlines the revised shareholding and encumbrance details for the promoters involved:

Name of Promoter	Number of Shares Pledged	Date of Creation	Post-Event Encumbered Holding (Shares)	Post-Event Encumbered Holding (%)
Aayush Agrawal Trust	38,32,651	2 June 2026 & 30 June 2026	1,14,45,087	9.16%
Gabs Investments Private Limited	27,70,000	2 June 2026	27,70,000	2.22%
Aayush Agrawal	30,000	30 June 2026	30,000	0.02%

The total encumbered shares reported in the revised disclosure stand at 1,42,45,087 shares, or 11.40% of the total share capital. The equity share capital of Ajanta Pharma remains at ₹24,98,71,248, comprising 12,49,35,624 equity shares with a face value of ₹2 each.